CLINICAL_TRIALS
trial_result
· 2016-08-18
Clinical Trial Update: Clinical Trial of Pioglitazone for Prevention of Cardiac Allograft Vasculopathy After Heart Transplantation [Phase 2]
Summary
A Phase 2 trial evaluating pioglitazone to prevent cardiac allograft vasculopathy after heart transplantation has completed, with results posted.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Stanford University | Conditions: Cardiac Allograft Vasculopathy | Phase 2 | Status: COMPLETED | Results posted: 2016-08-18